MRTX0902 (compound 32) (25, 50 mg/kg; p.o.; twice daily; 25 d) shows anti-tumor effect in mouse model and results tumor regression[1].
MRTX0902 (1-3 mg/kg for i.v. or 10-30 mg/kg for p.o.; single dose) exhibits good brain penetrance, low clearance, and high bioavailability[1].
PK Parameters for MRTX0902 across Species[1]
| Parameter | Route | Dose (mg/kg) | Cl (mL/min/kg) | Vd,ss (L/kg) | T1/2(iv) (h) | F (%) |
| Mouse | IV/PO | 3/30 | 4.4 | 0.28 | 1.3 | 69 |
| Rat | IV/PO | 1/10 | 14.6 | 0.28 | 0.62 | 83 |
| Dog | IV/PO | 2/10 | 7.6 | 0.48 | 0.86 | 38 |
| Animal Model: | Female CD-1 mice[1] |
| Dosage: | 50 mg/kg |
| Administration: | Oral gavage; twice daily; 1 day |
| Result: | Resulted free drug exposure in the brain as well as the efflux ratio in the Caco-2 assay (ER = 1.5).
Showed short half-life of the compound in mice (T1/2= 1.3 h). |
| Animal Model: | MIA PaCa-2 xenograft model in mouse[1] |
| Dosage: | 25 mg/kg; 50 mg/kg |
| Administration: | Oral gavage; twice daily; 25 days |
| Result: | Reduced tumor growth by 41% and 53% at 25 mg/kg and 50 mg/kg administration. |